Antibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- BAF633 - Provider product page
- Provider
- Novus Biologicals
- Product name
- Goat Polyclonal TRAILR4/TNFRSF10D/DcR2 Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects human TRAIL R4/TNFRSF10D in ELISAs and Western blots. In sandwich immunoassays, less than 3.5% cross-reactivity with recombinant human (rh) TRAIL R3 is observed and less than 0.5% cross-reactivity with rhTRAIL R1, rhTRAIL R2, rhTRAIL, rhTNF-alpha , and rhTNF-beta is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Biotin
- Isotype
- IgG
- Vial size
- 50 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
Submitted references Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade.
Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin.
Reddy RM, Yeow WS, Chua A, Nguyen DM, Baras A, Ziauddin MF, Shamimi-Noori SM, Maxhimer JB, Schrump DS, Nguyen DM
Apoptosis : an international journal on programmed cell death 2007 Jan;12(1):55-71
Apoptosis : an international journal on programmed cell death 2007 Jan;12(1):55-71
Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin.
Tsai WS, Yeow WS, Chua A, Reddy RM, Nguyen DM, Schrump DS, Nguyen DM
Molecular cancer therapeutics 2006 Dec;5(12):2977-90
Molecular cancer therapeutics 2006 Dec;5(12):2977-90
No comments: Submit comment
No validations: Submit validation data